Crescita Therapeutics Inc.
CTX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.44% | -340.80% | 171.97% | 185.24% | -39.87% |
| Total Depreciation and Amortization | 13.13% | 13.08% | 21.85% | 14.81% | -13.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 424.06% | 439.28% | -618.55% | -218.68% | 2.45% |
| Change in Net Operating Assets | 369.52% | -65.39% | -31.45% | -195.99% | -80.30% |
| Cash from Operations | 128.57% | -69.64% | 173.91% | -100.55% | -227.46% |
| Capital Expenditure | 71.96% | 85.49% | 2.28% | 81.56% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 154.78% | 123.91% | -7.83% | 81.56% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -46.02% | -7.27% | -5.45% | -7.41% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -3.42% | -22.92% | 44.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00% | -- | -- | -- |
| Cash from Financing | 62.36% | 10.04% | -4.27% | -9.52% | 36.69% |
| Foreign Exchange rate Adjustments | 380.95% | -131.00% | 164.00% | -248.28% | -30.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.67% | -67.64% | 121.39% | 32.53% | -572.85% |